跳至主要内容
临床试验/NCT04613544
NCT04613544Unknown不适用

A Prospective, Open Label, Multi-Center, Pilot Study to Assess Safety, Efficacy and Usability of Application for Atrial Fibrillation Vocal Marker

Cardiokol Ltd2 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2020年4月7日最近更新:
适应症

试验速览

阶段
不适用
发起方
Cardiokol Ltd
入组人数
400
试验地点
2
主要终点
Safety Assessment

研究概览

简要总结

Voice Assist Arrhythmia Monitoring (VAAM) is an application running on smartphones and/or landline phones that performs vocal tests for the monitoring of abnormalities in the heart rhythm.

详细描述

Following ICF signature and process and eligibility confirmation, subject will have a training session to assure correct application use. The subjects will be asked to pronounce few vowels 3 times a day to be evaluated by the application analysis algorithm at the patient natural environment.

At the same time, a single lead ECG system will be recorded synchronously ECG for reference with the use of dedicated recording device

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Female and male at age of ≥18 years and above.
  • All AF types Or Medical history of Cryptogenic stroke.
  • Ability and willingness to sign an informed consent form

排除标准

  • Subjects with implanted cardiac defibrillators or pacemakers neurostimulators and/or body worn medical devices such as insulin pumps.
  • Subjects diagnosed with any heart arrhythmias other than A-Fib, except for PVC.
  • Patient who underwent cardioversion or ablation in the last year and is in stable sinus rhythm.
  • Women who are pregnant or breastfeeding (women of child-bearing potential must provide a declaration stating that they are not pregnant)
  • Tremor or Parkinson's disease
  • Current hoarseness
  • Barriers for communication and lack of capability to execute the handlings required for this study.
  • Subjects who are currently enrolled in another clinical investigation. Parallel Enrollment to a non-interventional study is permitted.

结局指标

主要结局

Safety Assessment

时间窗: 6 weeks

related Adverse device effect

次要结局

  • Usability(6 weeks)
  • Effectivness(6 wweeks)

研究者

发起方
Cardiokol Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验